Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
Company Ended the Quarter With Cash of Approximately $527.0 Million NEW YORK, Feb. 04, 2022…
Company Ended the Quarter With Cash of Approximately $527.0 Million NEW YORK, Feb. 04, 2022…
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 04, 2022 (GLOBE NEWSWIRE) —…
Vancouver, British Columbia–(Newsfile Corp. – February 4, 2022) – Abner Labs announces the appointment of…
Improved Conditions and Execution Drive Strong Finish to 2021 and Favorable 2022 Outlook BROOKLYN HEIGHTS,…
Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion Posts Fourth Quarter…
Net Sales Increased 2.9% and Organic Net Sales Increased 1.6% Income from Continuing Operations Decreased…
Fourth Quarter Earnings Per Share of $1.37 and Record Fourth Quarter Adjusted Earnings Per Share…
NEW YORK & LONDON & MUMBAI, India–(BUSINESS WIRE)–#BPM–WNS (Holdings) Limited (NYSE: WNS), a leading provider…
This New Combined Business Is Intended to Be Separated From Spectrum Brands, Creating a New…
Results to impact ColoAlert profile for FDA submission Provides opportunity for ColoAlert to achieve gold…
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company…
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4,…
Strong 2021 sales and business EPS(1) growth enabling increased investment in R&D Paris, February 4,…
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus…
Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis…
NEW YORK–(BUSINESS WIRE)–Silver Spike Investment Corp. (“SSIC”), a newly-organized closed-end management investment company that has…
Toronto, Ontario–(Newsfile Corp. – February 3, 2022) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or…
NEW YORK–(BUSINESS WIRE)–theMaven, Inc. (OTCQX: MVEN), currently operating under the brand name The Arena Group…
First-ever lentiviral hematopoietic stem cell gene therapy approved for reimbursement by NHS England Two children…
BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology…